Currency In USD
| Previous Close | 1.78 |
| Open | 1.84 |
| Day High | 1.84 |
| Day Low | 1.73 |
| 52-Week High | 4.59 |
| 52-Week Low | 1.67 |
| Volume | 10,945.52 |
| Average Volume | 15,482 |
| Market Cap | 4.22M |
| PE | -0.89 |
| EPS | -1.95 |
| Moving Average 50 Days | 2.04 |
| Moving Average 200 Days | 2.76 |
| Change | -0.05 |
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
GlobeNewswire Inc.
Mar 02, 2026 11:30 AM GMT
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injur